Levacetylleucine (Aqneursa) improved functioning in a phase III crossover trial of adults and children with ataxia-telangiectasia. Two patients had three treatment-emergent adverse events; none were ...

(BHVN) closed 7% higher on Wednesday on the heels of hitting enrollment milestones in two high-priority clinical programs, ...

Incubated by Houston-based Fannin Innovation Studio, the 11h drug created in Nebraska will move toward phase 1 clinical ...

IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...

Prime Minister Sir Kier Starmer was challenged to help Jake in the House of Commons ...

Shares of Larimar Therapeutics, Inc. (LRMR) jumped 3% after hours on Wednesday after its director, Thomas E. Hamilton, ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary ...

Eimear McAndrew was diagnosed with early-onset Spinocerebellar Ataxia 7 (SCA7) at 27 years old, which is an aggressive ...

Drivers have been told that if they do not act correctly, they could face serious consequences ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 19, ...

Our latest CPD module explores five common but challenging neurology cases encountered in general practice, and discusses evidence-based approaches to assessment, investigation and management.

Did you know you can manage your profile, and explore all of the available newsletters from Kilkenny Live within your account ...